C‐Myc participates in β‐catenin–mediated drug resistance in A549/DDP lung adenocarcinoma cells

The aim of this study was to investigate c‐Myc and β‐catenin–mediated drug resistance in A549/DDP lung adenocarcinoma cells. Cisplatin sensitivity was determined by the 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) toxicity assay. β‐Catenin and c‐Myc protein expression following cisplatin treatment were determined using western blotting and immunofluorescence. Flow cytometry was performed to detect cell cycle and apoptosis in A549, A549/DDP, and c‐Myc small interfering RNA (siRNA)–transfected A549/DDP cells before and after treatment with different doses of cisplatin. The median inhibitory concentration (IC50) in cisplatin‐treated A549 and A549/DDP cells was 5.769 ± 0.24 μmol/L and 28.373 ± 0.96 μmol/L, respectively; the cisplatin resistance of A549 cells was about five times that of A549/DDP cells. Endogenous β‐catenin and c‐Myc expression in A549/DDP cells were higher than that in A549 cells, and were upregulated in A549/DDP cells (p < 0.05) and downregulated in A549 cells after 48 h cisplatin treatment (p < 0.05). β‐catenin localization transferred from membrane/cytoplasmic/nuclear to cytoplasmic/nuclear, and c‐Myc localization transferred from cytoplasmic/nuclear to nuclear in both cell lines following cisplatin treatment. The rate of apoptosis increased in a dose‐dependent manner with cisplatin. After 48‐h transfection with c‐myc siRNA, A549/DDP cells were blocked in the S phase, and G0/G1‐phase cells increased. Simultaneously, the apoptotic rate was increased (p < 0.05) and the IC50 decreased significantly (p < 0.05). C‐myc, the downstream target gene of β‐catenin, plays an important role in regulating cisplatin resistance in A549/DDP cells. C‐Myc siRNA improved the sensitivity of A549/DDP cells to cisplatin.

[1]  E. Wang,et al.  Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells. , 2013, Cancer letters.

[2]  Slovénie Pyndiah,et al.  Un trio de choc pour pallier la chimiorésistance des cancers : c-MYC, PARP1, BIN1 , 2013 .

[3]  G. Bidwell,et al.  Thermally Targeted Delivery of a c-Myc Inhibitory Polypeptide Inhibits Tumor Progression and Extends Survival in a Rat Glioma Model , 2013, PloS one.

[4]  S. Pyndiah,et al.  [c-MYC, PARP1 and BIN1 as targets for therapy of cancer cell resistance]. , 2013, Medecine sciences : M/S.

[5]  J. Marin,et al.  Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. , 2012, Molecular pharmaceutics.

[6]  B. Seifert,et al.  c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients , 2011, BMC Cancer.

[7]  Y. Jeng,et al.  Role of p53 and β-catenin Mutations in Conjunction with CK19 Expression on Early Tumor Recurrence and Prognosis of Hepatocellular Carcinoma , 2011, Journal of Gastrointestinal Surgery.

[8]  Sonali M. Smith,et al.  The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. , 2010, Blood cells, molecules & diseases.

[9]  H. Su,et al.  Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway , 2010, International journal of cancer.

[10]  Sai-Wen Tang,et al.  MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. , 2009, Cancer letters.

[11]  X. Hong,et al.  Retraction: siRNA directed against c-Myc inhibits proliferation and downregulates human telomerase reverse transcriptase in human colon cancer Colo 320 cells , 2008, Journal of experimental & clinical cancer research : CR.

[12]  D. Stearns,et al.  RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells , 2009, BMC Cancer.

[13]  Si Zhang,et al.  Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells. , 2008, Biochimica et biophysica acta.

[14]  X. Hong,et al.  siRNA directed against c-Myc inhibits proliferation and downregulates human telomerase reverse transcriptase in human colon cancer Colo 320 cells , 2008, Journal of experimental & clinical cancer research : CR.

[15]  Li Lin,et al.  [Establishment and biological characteristics of a multi-drug resistant cell line A549/Gem.]. , 2008, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[16]  Sanjeev Banerjee,et al.  c-Myc–Induced Chemosensitization Is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-κB Activity in Pancreatic Cancer Cells , 2007, Clinical Cancer Research.

[17]  J. Lovén,et al.  c‐Myc‐dependent etoposide‐induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling , 2006, Journal of cellular biochemistry.

[18]  K. Vasquez,et al.  Targeting oncogenes to improve breast cancer chemotherapy. , 2006, Cancer research.

[19]  Y. Doki,et al.  Clinical significance of the second cycle response to cisplatin‐based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma , 2006, Journal of surgical oncology.

[20]  J. Wysolmerski,et al.  Key stages of mammary gland development: Molecular mechanisms involved in the formation of the embryonic mammary gland , 2005, Breast Cancer Research.

[21]  Hongxia Zhu,et al.  Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo , 2004, Breast Cancer Research.

[22]  K. Taira,et al.  Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  J. Kigawa,et al.  Expression of the c‐myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer , 2004, Cancer science.

[24]  J. Cleveland,et al.  c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-XL , 2003, Molecular and Cellular Biology.

[25]  J. Isola,et al.  Amplification of c-myc by Fluorescence In Situ Hybridization in a Population-Based Breast Cancer Tissue Array , 2001, Modern Pathology.

[26]  J. Sedivy,et al.  c-Myc Is Necessary for DNA Damage-Induced Apoptosis in the G2 Phase of the Cell Cycle , 2001, Molecular and Cellular Biology.

[27]  G. Zupi,et al.  c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. , 2001, Molecular pharmacology.

[28]  A. Scorilas,et al.  Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis , 1999, British Journal of Cancer.

[29]  C. Leonetti,et al.  Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  J. Foekens,et al.  Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[31]  J. Foekens,et al.  Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. , 1992, European journal of cancer.